Clinical characteristics, treatment, and long-term outcomes in 987 patients with splenic marginal zone lymphoma to inform treatment and surveillance strategies

医学 脾边缘带淋巴瘤 脾切除术 美罗华 内科学 淋巴瘤 累积发病率 生存分析 外科 年轻人 侵袭性淋巴瘤 入射(几何) 死亡率 存活率 回顾性队列研究 肿瘤科 总体生存率 儿科 胃肠病学 血液学 病历 化疗 脾脏 死因
作者
Ahmed Ludvigsen Al‐Mashhadi,Mikkel Runason Simonsen,Elizabeth Smyth,Rose‐Marie Amini,Bente Arboe,James R. Cerhan,Iman Chanchiri,Chan Yoon Cheah,Jonathan R Day,Toby Andrew Eyre,Anne Ortved Gang,Hervé Ghesquières,Thomas Matthew Habermann,Eliza Anne Hawkes,Steven Hwang,Ruxandra Maria Irimia,Jennifer Bøgh Jørgensen,Arushi Khurana,Claire Maquet,Mathew S. Maurer
出处
期刊:Blood Cancer Journal [Springer Nature]
标识
DOI:10.1038/s41408-026-01660-2
摘要

Splenic Marginal Zone Lymphoma (SMZL) is an indolent non-Hodgkin lymphoma subtype. Due to its rarity, evaluation of real-world data is necessary to inform clinical practice. In this study, adults diagnosed with SMZL between 2000 and 2018 from North America, Europe, and Australia were included and followed until death or last visit. Data were extracted from medical records and regional/national registries. In total, 987 patients with median age of 68 years were included. The 10-year overall survival (OS) estimates were 59% (95%CI: 55-63) from first-line treatment and 49% (95%CI: 43-57) from second-line treatment. First-line splenectomy ( n = 434) and rituximab monotherapy ( n = 121) were associated with an Inverse Probability of Treatment Weighting (IPTW)-adjusted 5-year failure-free survival (FFS) of 52% for splenectomy versus 42% for rituximab; HR 0.70 (95%CI: 0.44-1.13) and adjusted HR for OS of 1.09 (95%CI: 0.59-2.01). The 10-year cumulative risk of transformation from diagnosis was 15% (95%CI: 12-18) with 5-year post-transformation OS of 38% (95%CI: 29-49), and 23% (95%CI: 13-41) for transformation after previous chemotherapy. Lower rates of transformation were seen in patients receiving frontline rituximab. While frontline therapy with either splenectomy or rituximab monotherapy had similarly favorable outcomes, patients had a persistent risk of progression and transformation andsurvival after transformation was poor.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
iii完成签到,获得积分10
2秒前
2秒前
张会完成签到,获得积分10
2秒前
2秒前
小博士328发布了新的文献求助10
3秒前
CodeCraft的应助被霸气雯采纳,获得10
3秒前
Hooooo完成签到 ,获得积分10
3秒前
3秒前
WangXingQuan发布了新的文献求助10
3秒前
bkagyin的应助被多喝水采纳,获得20
3秒前
唯恋完成签到,获得积分10
4秒前
令狐惜海的应助被诚心的夏槐采纳,获得10
4秒前
4秒前
情怀的应助被jklp采纳,获得10
5秒前
badada发布了新的文献求助10
5秒前
5秒前
CAOHOU的应助被obaica采纳,获得10
5秒前
kjh发布了新的文献求助10
6秒前
6秒前
Ann发布了新的文献求助10
6秒前
6秒前
飞远发布了新的文献求助10
6秒前
7秒前
lyh完成签到,获得积分10
8秒前
8秒前
倾听阳光完成签到,获得积分10
9秒前
9秒前
当0卷死坏女人完成签到,获得积分10
9秒前
Akim的应助被怕黑冥王星采纳,获得10
9秒前
Makoto1377完成签到,获得积分10
9秒前
Rida302完成签到,获得积分10
10秒前
念姬发布了新的文献求助10
10秒前
10秒前
酷波er的应助被WangXingQuan采纳,获得10
11秒前
隐形曼青的应助被Gibson采纳,获得10
12秒前
溧谦发布了新的文献求助10
12秒前
12秒前
停云发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183601
求助须知:如何正确求助?哪些是违规求助? 9572875
关于积分的说明 21827816
捐赠科研通 7780716
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558197
邀请新用户注册赠送积分活动 2480485